LOW-VOLUME · PRURITUS

oritavancin Side Effects

oritavancin (also sold as Orbactiv) is a LOW-VOLUME FAERS extract #493 of 524 by FAERS report count. Still opens on PRURITUS: PRURITUS leads at 162 reports (18.1% of the book).

Data updated 2026-05-15

896
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

Among 896 FAERS reports for oritavancin, PRURITUS is the most-reported reaction (162). Volume band LOW-VOLUME #493 of 524 by FAERS report count.

Thinner FAERS extract for oritavancin (Orbactiv) (896 reports #493 of 524 by FAERS report count). PRURITUS leads at 162 reports (18.1% of the book). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2014–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

PRURITUS leads 162 of 896 reports

PRURITUS
162
URTICARIA
105
RASH
84
CHILLS
83
BACK PAIN
81
DYSPNOEA
74
NAUSEA
67
INFUSION RELATED REACTION
60
ERYTHEMA
58
CHEST PAIN
54
FLUSHING
41
VOMITING
41
HEADACHE
39
RED MAN SYNDROME
38
TREMOR
35
HYPERSENSITIVITY
33
PYREXIA
28

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 336 (52%)
Male 313 (48%)

Age peak 45-64 (180 reports)

0-17 10 (2%)
18-44 130 (27%)
45-64 180 (38%)
65-74 66 (14%)
75+ 89 (19%)

FAERS filings rising toward 2025

14
15
16
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Death appears on 30 reports (3.3% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 7
CARDIAC ARREST 5
BACK PAIN 4
DYSPNOEA 4
NAUSEA 4
BLISTER 3
CHILLS 3
DRUG RESISTANCE 3
ACUTE KIDNEY INJURY 2
CARDIAC FAILURE CONGESTIVE 2
INFUSION RELATED REACTION 2
PRURITUS 2
SEPSIS 2
URTICARIA 2
VOMITING 2
ABDOMINAL PAIN 1
ACUTE MYELOID LEUKAEMIA 1
ACUTE MYOCARDIAL INFARCTION 1

Reactions in Hospitalization Reports

Hospitalization mid-share (161, 18.0%). Co-reported reactions:

Reaction Reports
CHILLS 31
DYSPNOEA 29
NAUSEA 19
BACK PAIN 16
CHEST PAIN 15
PYREXIA 14
VOMITING 14
INFUSION RELATED REACTION 13
AGRANULOCYTOSIS 12
TACHYCARDIA 12
PRURITUS 10
URTICARIA 10
ERYTHEMA 9
TREMOR 9
HYPOTENSION 8
MULTIPLE USE OF SINGLE-USE PRODUCT 8
RASH 8
DIZZINESS 7
How to read oritavancin FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)

FAERS holds 896 voluntary reports linked to oritavancin (Orbactiv), 2014-2025. Death is listed on 30 (3.3%). Hospitalization appears on 161 (18.0%). Top co-reported indication: Product Used For Unknown Indication.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with oritavancin

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.